Impact Of Rising Cancer And Infectious Diseases On The Viral Vector Manufacturing Market Driving Market Acceleration in the Viral Vector Manufacturing Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Viral Vector Manufacturing Market Size By 2025?
The market size of viral vector manufacturing has seen substantial expansion in the past few years. Its projected growth is from $6.93 billion in 2024 to an expected $8.33 billion in 2025, with a compound annual growth rate (CAGR) of 20.1%. The surge observed in the historic period is due to factors like the growth in gene therapies pipeline, clinical success and approvals, escalated investment in biopharmaceuticals, and a rise in the occurrences of genetic disorders.

How Big Is the Viral Vector Manufacturing Market Size Expected to Grow by 2029?
The market for viral vector manufacturing is anticipated to witness a significant surge in the upcoming years, expanding to a valuation of $17.68 billion by 2029, with a compound annual growth rate (CAGR) of 20.7%. This projected increase during the forecast period can be linked to various contributing factors such as the broadening use in the field of oncology, international cooperation in gene therapy research, the uptake of viral vectors in the creation of vaccines, ongoing clinical trials and commercialization. Key trends foreseen in the forecast period involve technological advancements in vector production, the introduction of next-gen vectors, adherence to regulatory norms and standardization, collaborations and partnerships, as well as worldwide expansion of manufacturing units.

View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Key Market Drivers Powering Viral Vector Manufacturing Market Expansion and Growth?
The viral vector manufacturing market is forecasted to grow due to the rising instances of cancer and infectious diseases. The term infectious disease is used to describe disorders caused by the presence or action of a virus or associated toxins which are transmitted to a vulnerable host because of an interaction with an infected individual, creature or object. Cancer is a general term for a variety of diseases that can occur in any body organ or tissue when rogue cells proliferate uncontrollably, infringing upon and invading adjacent tissues, and metastasizing to other organs. To provoke the body's anti-cancer immune response, tumor antigens or proteins on tumor cells are produced through viral vectors. In both pre-clinical and clinical experiments, viral vectors have been utilised as vaccines against a variety of infectious diseases. For exemplification, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported a significant increase in diagnosed cancer cases from 160,570 in 2022 to 164,694 in 2023. This represents an ascending trend in cancer incidence within Australia. Elaborating further, in August 2024, data from the UK Health Security Agency indicated that England had 368 reported measles cases in 2023, a near sevenfold increase from the 53 cases reported in 2022. Notably, 44% of these cases were from the West Midlands and 33% from London. Consequently, the escalating prevalence of cancer and infectious diseases is triggering the growth of the viral vector manufacturing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Viral Vector Manufacturing Market?
A prominent trend being noticed in the viral vector manufacturing market is that of product innovation. Companies with a major presence in this market are focusing on introducing innovative products in a bid to maintain their market standing. For example, Merck KGaA, a science and technology firm based in Germany, in August 2022, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This company is among the first Contract Development and Manufacturing Organizations (CDMOs) and technology inventors to provide a comprehensive package of viral vector manufacturing, that includes AAV, Lentiviral, CDMO, CTO, and process development. Through this advanced platform, biopharmaceutical companies can reduce the cost and duration of process development, simultaneously expediting the clinical manufacturing time.

What Are the Emerging Segments in the Viral Vector Manufacturing Market?
The viral vector manufacturing market covered in this report is segmented -

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types
2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research
5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:
1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26
2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others
3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others
4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others
5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

Who Are the Global Leaders in the Viral Vector Manufacturing Market?
Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Which are the Top Profitable Regional Markets for the Viral Vector Manufacturing Industry?
North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12398

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.